Quarterly ResultAug 4, 2026, 04:06 PM
Spyre Reports Positive Phase 2 Data for SPY001/SPY002; $1.1B Cash
AI Summary
Spyre Therapeutics announced its second quarter 2026 financial results and provided program updates. The company reported positive topline induction data for SPY001 and SPY002 from the Phase 2 SKYLINE trial, demonstrating best-in-class efficacy potential and a consistent safety profile. Enrollment for the Phase 2 SKYWAY basket trial is complete, with upcoming data readouts for rheumatoid arthritis in September and psoriatic arthritis/axial spondyloarthritis in Q4 2026. Spyre ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2029, while reporting a net loss of $36.2 million.
Key Highlights
- Positive topline Phase 2 data for SPY001 and SPY002 in UC, demonstrating best-in-class efficacy potential.
- SPY001 achieved 40% clinical remission and 51% endoscopic improvement in UC patients.
- SPY002 achieved 33% clinical remission and 42% endoscopic improvement in UC patients.
- Enrollment completed for Phase 2 SKYWAY trial in rheumatic diseases, with all sub-studies over-enrolling.
- Cash, cash equivalents, and marketable securities totaled $1.1 billion as of June 30, 2026.
- Expected cash runway extends into the second half of 2029.
- Net loss for Q2 2026 was $36.2 million, compared to $36.7 million in Q2 2025.
- R&D expenses increased to $65.5 million in Q2 2026 from $40.1 million in Q2 2025.
Price Impact
More from SYRE